Skip to content

INVESTORS & MEDIA

Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Sep 11, 2017
Health Canada New Drug Submission (NDS) planned based on Phase 1 and 2 clinical results and supported by available data from anticipated MATCH and ALLELE Phase 3 studies, which are expected to be ongoing at the time of NDS filingHealth Canada regulatory feedback similar to scientific advice from European Medicines Agency's ...
Sep 5, 2017
SOUTH SAN FRANCISCO, Calif., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading "off-the-shelf" T-cell immunotherapy company developing novel treatments for patients with cancer and autoimmune diseases, today announced that ATA230 was granted orphan drug designation for the treatment of cytom...
Aug 31, 2017
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading "off-the-shelf" T-cell immunotherapy company developing novel treatments for patients with cancer and multiple sclerosis (MS) today announced that the Company will participate in three upcoming investor conferen...
Aug 22, 2017
SOUTH SAN FRANCISCO, Calif., Aug. 22, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading "off-the-shelf" T-cell immunotherapy company developing novel treatments for patients with cancer and multiple sclerosis (MS), today announced that Atara's board of directors approved a grant, effective as of Augus...
Aug 22, 2017
SOUTH SAN FRANCISCO, Calif., Aug. 22, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading "off-the-shelf" T-cell immunotherapy company developing novel treatments for patients with cancer and multiple sclerosis (MS), today announced the appointment of Kanya Rajangam, M.D., Ph.D., as Senior Vice Presi...
Aug 7, 2017
SOUTH SAN FRANCISCO, Calif., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading "off-the-shelf" T-cell immunotherapy company developing novel treatments for patients with cancer and multiple sclerosis (MS), today reported financial results for the second quarter of 2017 and recent operational ...
Aug 2, 2017
SOUTH SAN FRANCISCO, Calif., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading "off-the-shelf" T-cell immunotherapy company developing novel treatments for patients with cancer and multiple sclerosis (MS), today announced that Isaac Ciechanover, M.D., the Company's President and Chief Executi...
Jul 31, 2017
New results characterizing the molecular signature of Epstein-Barr Virus (EBV) in MS brain lesions will also be presented Presentations to take place during the upcoming MSParis2017 Congress, the 7th Joint Meeting of the European Committee for Trea...
May 24, 2017
SOUTH SAN FRANCISCO, Calif., May 24, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced that the Company will present at three upcoming investor conferences in June: Jefferies 2017 Global Healthcare Conference Isaac Ciechanover, M.D., the Company...
May 10, 2017
SOUTH SAN FRANCISCO, Calif., May 10, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced that the compensation committee of Atara's board of directors, approved a grant, effective as of May 10, 2017, to Dr. Derrell Porter in connection with his employment at the Company, of a non-qualified stock...
May 10, 2017
SOUTH SAN FRANCISCO, Calif., May 10, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced the appointment of Dr. Derrell Porter as Senior Vice President and Global Commercial Head. Dr. Porter brings extensive commercialization experience to the management team as Atara moves towards Phase 3 studies of...
May 4, 2017
SOUTH SAN FRANCISCO, Calif., May 04, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today reported financial results for the first quarter of 2017 and recent operational highlights. "We continued to make important progress advancing our robust pipeline of T-cell therapies in the first quarter," ...
Apr 21, 2017
SOUTH SAN FRANCISCO, Calif., April 21, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases, today announced that it has entered into a clinical trial collaboration agreement with Merck ...
Apr 20, 2017
Encouraging Clinical Improvements Correlate with EBV Reactivity   Presentation Selected for Emerging Science and Conference Press Programs by AAN SOUTH SAN FRANCISCO, Calif., April 20, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (...
Apr 3, 2017
SOUTH SAN FRANCISCO, Calif., April 03, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific innovation, today announced that it has appointed Mr. Joe Newell as...
Page:
...
Next Last
 
= add release to Briefcase